gucag006
Oct 1, 3:10 PM
$CORT With 9.4M shares shorted, which is about 9% outstanding or 11% float, we will only trade sideways for a while until the next catalysts such as Relacorilant/CS approval in US, Lifyorli approval in EU, and/or Q3 ER - all in 2027. These catalysts should advance SP to north of
$150.
More exciting are the clinical advancement of Dazucorilant/ALS and Miricorilant/MASH to P3 trials. Hopefully, at least one of the two will be in H1/27, or both. The initiation of these two P3 trials will further advance SP to above
$200.
Then in 2028, we should see all four franchises firing - CS, PROC, ALS, and MASH, which are all
$B- dollar blockbuster drugs. If not acquired and no split by then, we should see SP reaches north of
$300. GL & cheers!
0 replies